Drug Database
IN

inactivated trivalent influenza vaccine (eTIV_f / Evagrip / Fluvirin)

✓ Approved

Novartis AG · Vaccine · Vaccine

What is inactivated trivalent influenza vaccine?

inactivated trivalent influenza vaccine is a vaccine developed by Novartis AG. It is approved for therapeutic indications via injectable (others) or intradermal injection or intramuscular (im) injection or subcutaneous injection.

Drug Profile

Brand NameseTIV_f, Evagrip, Fluvirin
CompanyNovartis AG
Drug ClassVaccine, Large Molecules
RouteInjectable (Others), Intradermal Injection, Intramuscular (IM) Injection, Subcutaneous Injection
StatusApproved

Related Research Articles

PubMedDiagnostic microbiology and infectious disease2026-07-25

Genomic evolution patterns of influenza A/H1N1 in Iraqi patients revealed by nanopore sequencing.

Owaid Farah M FM, Fadhil Hula Y HY

Influenza viruses have high mutation rates and cause serious health problems worldwide. In our population, no study has examined mutations and their variation relative to the wild-type and vaccine strains. Study focused on whole-genome sequencing to characterize the virus, construct phylogenetic trees, analyze mutations, and assess nucleotide diversity. Nasal swabs were collected from 170 patients with RTI (SARI or ILI) in Baghdad and Wasit from November 2024 to March 2025, and tested for influenza A virus detection and typing by real-time reverse transcription polymerase chain reaction. The 14 positive viral genomes were sequenced using the MinION nanopore platform. 49 influenza viral genomes were identified as positive cases, comprising 48 A/H1N1 and 1 A/H3N2 strain. Nine complete A/H1N1 were sequenced, revealing nonsynonymous mutations, especially in the hemagglutinin (HA), neuraminidase (NA), and nonstructural protein 1 (NS1) genes. Nucleotide diversity analysis revealed negative selection in certain A/H1N1 genes. Mutations were detected in antigenic and functional regions of HA and NA, indicating ongoing antigenic drift in circulating strains. Phylogenetic analysis showed that the Iraqi isolates were closely related to contemporary regional and global strains reported from neighboring countries such as Iran and Saudi Arabia, and were partially genetically related to recent vaccine strains such as A/Wisconsin/67/2022 and A/Missouri/11/2025. By contrast, the older vaccine strains suggest that Iraqi influenza viruses are evolving slowly, accumulating mutations continuously, while the important internal proteins are conserved. Mutations across all eight genome segments will be crucial for elucidating the genetic evolution of influenza A viruses in Iraq.

PubMedImmunological reviews2026-07-25

The Dual Role of Preexisting Immunity in Influenza: Protective Recall Versus Constraint of Novel Responses.

Fox Annette A, Zhu Ziheng Z, Sánchez-Ovando Stephany S

Preexisting immunity to influenza confers rapid protection against antigenically matched viruses but can also constrain responses to drifted variants. This review asks when and why prior infection or vaccination is protective versus detrimental, and which biological mechanisms-epitope masking by circulating antibody, inhibitory FcγRIIb signaling, and competitive dominance by affinity-matured memory B cells-drive these outcomes. We synthesize human cohort, serological, and vaccine-effectiveness data with mechanistic mouse and fate-mapping studies to explore how vaccine formulation, antigen dose, antigenic distance and T cell help modulate the balance between memory recall and recruitment of naïve B cells. Finally, we outline strategies (higher dose, adjuvants, multivalent display, and considered strain selection) to restore de novo responses against escape epitopes and improve vaccine performance.

PubMedFrontiers in public health2026-07-25

Respiratory symptoms, vaccination coverage, and antibiotic use among Hajj pilgrims: a multi-season cross sectional study (2023-2025).

Qashqari Fadi S I FSI

Respiratory tract infections are the most frequently reported illnesses during Hajj, one of the world's largest recurring mass gatherings. The convergence of millions of pilgrims from diverse geographic regions in Makkah, Saudi Arabia creates conditions conducive to the transmission of respiratory pathogens. Understanding patterns of infection, vaccination coverage, and antibiotic use across multiple seasons is essential to inform preventive strategies. A multi-season cross-sectional study was conducted during three consecutive Hajj seasons (2023-2025). Adult pilgrims were recruited and interviewed using a standardized structured questionnaire. Data collected included sociodemographic characteristics, vaccination history (meningococcal, influenza, COVID-19, pneumococcal), comorbidities, smoking behavior, respiratory symptoms, healthcare-seeking behavior, and antibiotic use. Multivariable logistic regression analyses were performed to identify factors independently associated with respiratory symptoms and antibiotic consumption. A total of 712 human participants (adult Hajj pilgrims) were enrolled. Overall, 38.9% reported at least one respiratory symptom at the time of assessment, with cough (28.1%), sore throat (23.5%), and runny nose (21.9%) being most common. Chronic lung disease (adjusted odds ratio [aOR] 2.36; 95% CI 1.42-3.92), presence of ≥1 chronic condition (aOR 1.58; 95% CI 1.12-2.24), and current smoking (aOR 1.74; 95% CI 1.15-2.63) were independently associated with respiratory symptoms. Influenza vaccination was associated with reduced odds of multi-symptom respiratory illness (aOR 0.72; 95% CI 0.53-0.98). Among symptomatic participants, 29.6% reported antibiotic use, frequently in the absence of febrile illness. Vaccination coverage was high for meningococcal vaccine (96.1%), while pneumococcal vaccination coverage remained lower. Respiratory symptoms remain a substantial health burden among Hajj pilgrims across consecutive seasons. Chronic lung disease and smoking increase susceptibility, while influenza vaccination appears protective. The frequent use of antibiotics highlights the need for strengthened antimicrobial stewardship. Enhanced vaccination uptake, targeted risk communication, and integrated prevention strategies are critical to mitigating respiratory infection risks during mass gatherings and safeguarding global public health.

PubMedWorld journal of emergency medicine2026-07-25

Evans syndrome following influenza A presenting with diffuse alveolar hemorrhage managed with extracorporeal membrane oxygenation.

Lu Haotian H, Shi Anke A, Yu Jieqiong J, Zhao Jing J et al.

PubMedJournal of the International AIDS Society2026-07-25

Behavioural and Structural Determinants of Mpox Vaccine Awareness and Uptake Among People With HIV in the Dominican Republic: A Cross-Sectional Study.

Paulino-Ramirez Robert R, Matias Wilfredo R WR, Chaumette Alexandre A, Lora-Rodríguez Hector H et al.

Mpox disproportionately affects people with HIV (PWH), yet little is known about mpox vaccine awareness and uptake in low- and middle-income countries. We evaluated mpox-related knowledge, attitudes and practices (KAP) among PWH in the Dominican Republic to identify determinants of vaccine awareness and uptake. We conducted a cross-sectional online survey of 98 PWH recruited through HIV clinics, community-based organizations and social networks (January-May 2025). The questionnaire assessed sociodemographic characteristics, mpox-related KAP, structural barriers and vaccination status. Univariable and multivariable logistic regression were used to examine factors associated with mpox vaccine awareness. Half of the participants (49/98) were aware of the mpox vaccine. Individuals aged 31-40 years had significantly lower odds of awareness compared with those aged 21-30 years. Despite high levels of formal education, 79% rated their mpox knowledge as low, and most perceived minimal personal risk. Among participants aware of the vaccine, 71% had been vaccinated. Structural barriers, including inconvenient site locations and logistical challenges, were frequently reported, even among vaccinated individuals, indicating that access limitations rather than hesitancy were the dominant constraints. Trust in vaccinating organizations was high overall, and healthcare providers and community organizations were the primary sources of vaccine information. Peer and community influence emerged as notable facilitators of uptake, while lack of reliable information and concerns about vaccine safety contributed to hesitancy. Mpox vaccine awareness among PWH in the Dominican Republic was low, but willingness to vaccinate was high when individuals were informed and able to access services. Strengthening mpox preparedness will require expanding accessible vaccination sites, improving disease-specific health literacy, and leveraging trusted community and clinical networks. Integrating mpox vaccination into routine HIV care delivery and enhancing community-led outreach may substantially improve uptake in this and similar low-middle income countries (LMIC) settings.

PubMedPneumonia (Nathan Qld.)2026-07-25

Pneumococcal pneumonia in adults - re-emergence of vaccine serotypes: a prospective multicenter cohort study in Germany, 2020-2023.

Bahrs Christina C, Rose Norman N, Barten-Neiner Grit G, Fleischmann-Struzek Carolin C et al.

The main burden of non-invasive pneumococcal diseases in adults is largely due to community-acquired pneumonia (CAP). This study aimed to investigate the distribution and dynamics of pneumococcal vaccine serotypes and to determine the proportion of CAP cases attributable to serotypes covered by 13-valent conjugate vaccine (PCV13), the 20-valent conjugate vaccine (PCV20), and the 23-valent polysaccharide vaccine (PPV23) among adults in Germany from 2020 to 2023. In this prospective multicenter cohort study, we analyzed all adult patients with CAP enrolled between January 1, 2020, and December 31, 2023, at 26 centers in Germany who provided urine samples for serotype-specific urine antigen detection (SSUAD) testing. Annual trends of pneumococcal vaccine serotypes from 2020 to 2023 were calculated for all patients and patient groups at risk using cluster-robust generalized linear models with heteroscedasticity-consistent standard errors. Of the 2,028 patients with all-cause CAP, 1,504 (1,008 patients aged ≥ 60 years, 373 younger patients with at least one comorbidity) had urine samples analyzed with SSUAD tests. Overall proportion of vaccine-type pneumococcal pneumonia among all-cause CAP for PCV13, PCV20, and PPV23 serotypes was 5.41% (95% CI 4.12-7.06%), 8.11% (95% CI 6.35-10.31%), and 8.31% (95% CI 6.27-10.93%), and serotype 3 was the most prevalent serotype (52 cases). Among patients aged ≥ 60 years, an increasing annual trend was observed for serotype 3 (OR 1.84, 95% CI 1.01-2.67), PCV13 (OR 1.89, 95% CI 0.89-2.89), PCV20 (OR 1.57, 95% CI 0.99-2.14), and PPV23 serotypes (OR 1.47, 1.04-1.91). The findings demonstrate that vaccine serotypes, particularly serotype 3, continued to circulate and reemerged among older adults with CAP in Germany.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about inactivated trivalent influenza vaccine